Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Youe-Kong Shue et al.		
Application No./Patent No.: 10/520,863 / 7,507,5		Filed/Issue Date: July 15, 2003 / March 24, 2009
Titled: Tiacumicin production		
Optimer Pharmaceuticals, Inc.	, a _corporatio	on
(Name of Assignee)		ssignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:		
1. X the assignee of the entire right, title, and	l interest in;	
2. an assignee of less than the entire right. (The extent (by percentage) of its owner.)		%); or
3. the assignee of an undivided interest in	the entirety of (a com	nplete assignment from one of the joint inventors was made)
the patent application/patent identified above, by vir	tue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy therefore is attached.		
OR		
		patent identified above, to the current assignee as follows:
1. From: DUFFIELD, JONATHAN	JAMES	To: OPTIMER PHARMACEUTICALS, INC.
The document was recorded in Reel 014016		Patent and Trademark Office at, or for which a copy thereof is attached.
2. From: SHUS, YOUE-KONG		To: OPTIMER PHARMACEUTICALS, INC.
	in the United States F ,Frame 0779	Patent and Trademark Office at, or for which a copy thereof is attached.
3. From: OKOUMU, FRANKLIN W	<i>I</i> .	To: OPTIMER PHARMACEUTICALS, INC.
	, Frame <u>0311</u>	Patent and Trademark Office at, or for which a copy thereof is attached.
Additional documents in the chain of it.	le are listed on a sup	pierrieritai sireet(s).
As required by 37 CFR 3.73(b)(1)(i), the docorron concurrently is being, submitted for record		of the chain of title from the original owner to the assignee was, CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of accordance with 37 CFR Part 3, to record the		nent document(s)) must be submitted to Assignment Division in ecords of the USPTO. <u>See</u> MPEP 302.08]
The undersigned (whose title is supplied below) is a	authorized to act on b	ehalf of the assignee.
/Robert Smyth/		January 14, 2011
Signature		Date
Robert Smyth		Attorney for Assignee
Printed or Typed Name		 Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: Youe-Kong Shue et al.		
Application No./Patent No.: 10/520,863 / 7,507,564	Filed/Issue Date: July 15, 2003 / March 24, 2009	
Titled: Tiacumicin production		
Optimer Pharmaceuticals, Inc, acorpora	tion	
(Name of Assignee) (Type of	Assignee, e.g., corporation, partnership, university, government agency, etc.	
states that it is:		
1. X the assignee of the entire right, title, and interest in;		
2. an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is	n %); or	
3. the assignee of an undivided interest in the entirety of (a co	omplete assignment from one of the joint inventors was made)	
the patent application/patent identified above, by virtue of either:		
the United States Patent and Trademark Office at Reel	n/patent identified above. The assignment was recorded in, Frame, or for which a	
copy therefore is attached. OR		
B. X A chain of title from the inventor(s), of the patent application	n/patent identified above, to the current assignee as follows:	
1. From: DU, CHI-JEN FRANK	To: OPTIMER PHARMACEUTICALS, INC.	
The document was recorded in the United States	s Patent and Trademark Office at	
Reel <u>015618</u> , Frame <u>0029</u>	or for which a copy thereof is attached.	
2. From: CHEN, YUAN-TING	To: OPTIMER PHARMACEUTICALS, INC.	
The document was recorded in the United States	s Patent and Trademark Office at	
Reel <u>015618</u> , Frame <u>0711</u>	, or for which a copy thereof is attached.	
3. From: CHIOU, MING-HSI	To: OPTIMER PHARMACEUTICALS, INC.	
The document was recorded in the United States	s Patent and Trademark Office at	
Reel <u>015618</u> , Frame <u>0822</u>	, or for which a copy thereof is attached.	
Additional documents in the chain of title are listed on a su	upplemental sheet(s).	
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence or concurrently is being, submitted for recordation pursuant to 3	e of the chain of title from the original owner to the assignee was, 7 CFR 3.11.	
[NOTE: A separate copy (i.e., a true copy of the original assign accordance with 37 CFR Part 3, to record the assignment in the	nment document(s)) must be submitted to Assignment Division in erecords of the USPTO. <u>See</u> MPEP 302.08]	
The undersigned (whose title is supplied below) is authorized to act on	behalf of the assignee.	
/Robert Smyth/	January 14, 2011	
Signature	Date	
Robert Smyth	Attorney for Assignee	
Printed or Typed Name	Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**